Mesenchymal stem cell therapy for recessive dystrophic epidermolysis bullosa: Prospects and clinical progress

Expert Opinion on Orphan Drugs

Volumn 4, Issue 4, 2016, Pages 343-345

  Rashidghamat, E ^a   Mellerio, J E ^a,b   Martinez, A E ^b   McGrath, J A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SUBPOPULATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EDITORIAL; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EPITHELIUM CELL; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 84961208563     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2016.1152886     Document Type: Editorial

References (15)

1. Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014; 70: 1103-1126
2. Prigione I, Benvenuto F, Bocca P, et al. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells. 2009; 27: 693-702
3. Ramasamy R, Fazekasova H, Lam EW, et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007; 83: 71-76
4. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003; 31: 890-896
5. Conget P, Rodriguez F, Kramer S, et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy. 2010; 12: 429-431
6. El Darouti M, Fawzy M, Amin I, et al. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: A randomized controlled trial. Dermatol Ther. 2015. DOI: 10.1111/dth.12305
7. Petrof G, Lwin SM, Martinez-Quiepo M, et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2015; 135: 2319-2321
8. Kühl T, Mezger M, Hausser I, et al. High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa. Mol Ther. 2015; 23: 1368-1379
9. Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010; 7: 629-639
10. Tolar J, McGrath JA, Osborn M. et al. Mucocutaneous engraftment and type VII collagen (C7) replacement after allogeneic hematopoietic cell transplantation (HCT) in patients with recessive dystrophic epidermolysis bullosa (RDEB); [. cited 2016 Jan 3 ]. Available from: Https://ash.confex.com/ash/2015/webprogram/Paper83725.html
11. Perdoni C, McGrath JA, Tolar J. Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res Ther. 2014; 5: 121
12. Tamai K, Yamazaki T, Chino T, et al. PDGFR alpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA. 2011; 108: 6609-6614
13. Iinuma S, Aikawa E, Tamai K, et al. Transplanted bone marrow-derived circulating PDGFR alpha-positive cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft. J Immunol. 2015; 194: 1996-2003
14. Almaani N, Nagy N, Liu L, et al. Revertant mosaicism in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2010; 130: 1937-1940
15. Tolar J, McGrath JA, Xia L, et al. Patient-specific naturally gene reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2014; 134: 1246-1254.